GB201002235D0 - Respiratory disease treatment - Google Patents

Respiratory disease treatment

Info

Publication number
GB201002235D0
GB201002235D0 GBGB1002235.8A GB201002235A GB201002235D0 GB 201002235 D0 GB201002235 D0 GB 201002235D0 GB 201002235 A GB201002235 A GB 201002235A GB 201002235 D0 GB201002235 D0 GB 201002235D0
Authority
GB
United Kingdom
Prior art keywords
respiratory disease
disease treatment
treatment
respiratory
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1002235.8A
Other versions
GB2477743A9 (en
GB2477743A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenta Therapeutics Ltd
Original Assignee
Argenta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Therapeutics Ltd filed Critical Argenta Therapeutics Ltd
Priority to GB1002235A priority Critical patent/GB2477743A/en
Publication of GB201002235D0 publication Critical patent/GB201002235D0/en
Publication of GB2477743A publication Critical patent/GB2477743A/en
Publication of GB2477743A9 publication Critical patent/GB2477743A9/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1002235A 2010-02-10 2010-02-10 Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds Withdrawn GB2477743A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1002235A GB2477743A (en) 2010-02-10 2010-02-10 Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1002235A GB2477743A (en) 2010-02-10 2010-02-10 Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds

Publications (3)

Publication Number Publication Date
GB201002235D0 true GB201002235D0 (en) 2010-03-31
GB2477743A GB2477743A (en) 2011-08-17
GB2477743A9 GB2477743A9 (en) 2012-04-04

Family

ID=42110502

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1002235A Withdrawn GB2477743A (en) 2010-02-10 2010-02-10 Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds

Country Status (1)

Country Link
GB (1) GB2477743A (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132928A2 (en) * 2005-06-03 2006-12-14 Case Western Reserve University Methods and compositions for treating inflammation
ES2654908T3 (en) * 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Thiazolidinedione analogues for the treatment of diseases mediated by metabolic inflammation
GB2465897B (en) * 2008-08-07 2011-02-09 Argenta Discovery Ltd Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Also Published As

Publication number Publication date
GB2477743A9 (en) 2012-04-04
GB2477743A (en) 2011-08-17

Similar Documents

Publication Publication Date Title
EP2629736A4 (en) Tissue treatment
EP2621588A4 (en) Methods and compositions for disease treatment using inhalation
GB2465897B (en) Respiratory disease treatment
EP2793986A4 (en) Respiratory treatment system including physiological sensors
PL2652193T3 (en) Treatment
EP2618878A4 (en) Therapeutic vaporizer
ZA201205829B (en) Treatment of respiratory disorders
EP2679140A4 (en) Medical endoscope system
GB201002243D0 (en) Respiratory disease treatment
EP2544686A4 (en) Combination methods for treatment of disease
EP2861244A4 (en) Sleep apnea treatment
GB201015822D0 (en) Medical ruggedised case
GB201002224D0 (en) Respiratory disease treatment
GB201013573D0 (en) Treatment
EP2601954A4 (en) Therapeutic agent for disease
IL232239A0 (en) Medical use
IL228589A0 (en) Therapeutic treatment
ZA201207696B (en) Compound for treatment of respiratory condition or disease
GB201014097D0 (en) Treatment
GB201002235D0 (en) Respiratory disease treatment
GB201001893D0 (en) Respiratory disease treatment
GB201001903D0 (en) Respiratory disease treatment
GB0910944D0 (en) Respiratory disease treatment
GB0901832D0 (en) Respiratory disease treatment
GB0901831D0 (en) Respiratory disease treatment

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)